According to DelveInsight's' estimates, the open-angle glaucoma market in the 7MM is expected to show positive growth, during the forecast period (2023–2032), mainly attributed to the launch of upcoming therapies and the increasing prevalence of open-angle glaucoma.

根据DelveInsight的估计，在预测期间（2023-2032年），预计7MM的开角型青光眼市场将呈现积极增长，主要原因是即将推出的治疗方法和开角型青光眼患病率的增加。

LAS VEGAS, Oct. 12, 2023 /PRNewswire/ -- DelveInsight's Open-Angle Glaucoma Market Insights report includes a comprehensive understanding of current treatment practices, open-angle glaucoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]..

拉斯维加斯，2023年10月12日/PRNewswire/-DelveInsight的开角型青光眼市场见解报告包括全面了解当前的治疗实践，开角型青光眼新兴药物，个体治疗的市场份额以及2019年的当前和预测市场规模到2032年，分为7MM[美国，EU-4（意大利，西班牙，法国和德国），英国和日本]）。。

Key Takeaways from the Open-Angle Glaucoma Market Report

开角型青光眼市场报告的主要收获

As per DelveInsight analysis, the open-angle glaucoma market is expected to grow positively at a significant CAGR during the study period (2019–2032).

根据DelveInsight分析，在研究期间（2019-2032年），开角型青光眼市场预计将在显着的CAGR下积极增长。

As per DelveInsight assessment, the highest diagnosed prevalent cases of open-angle glaucoma was estimated in the US in 2022, with 2.2 million cases which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.

根据DelveInsight评估，2022年美国估计诊断最多的开角型青光眼流行病例，其中220万例由于诊断测试的改进和人口的增加，预计很快就会急剧上升。

Leading open-angle glaucoma companies such as Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others are developing novel open-angle glaucoma drugs that can be available in the open-angle glaucoma market in the coming years..

领先的开角型青光眼公司，如Nicox Ophthalmics，Sun Pharma Advanced Research Company Limited（SPARC），Visiox Pharma，TearClear，Glaukos Corporation，Ono Pharmaceutical，Santen Pharmaceuticals，Omikron Italia S.r.l.，OPIS Spain，D.Western Therapeutics Institute（DWTI），Ocular Therapeutix，Inc.，MediPrint Ophthalmics（前身为Leo Lens Pharma），Tarsier Pharma，Peregrine Ophthalmic，Ocuphire Pharma，Qlaris Bio，Inc.，Betaliq，Inc.，VivaVision Biotech，Inc.，Abbvie等正在开发可用于开角型青光眼市场的新型开角型青光眼药物未来几年。。

Some key therapies for open-angle glaucoma treatment include NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others..

开角型青光眼治疗的一些关键疗法包括NCX-470，PDP-716（酒石酸溴莫尼定眼用混悬液），TC-002（拉坦前列素），iDose TR（曲伏前列素眼内植入物），Sepetaprost/DE-126/ONO-9054/STN-1012600，Catioprost/DE-130A/STN1013001，胞磷胆碱滴眼液2%，H-1337，OTX-TIC，LL-BMT1，TRS01，POLAT-001（脂质体拉坦前列素），Nyxol（甲磺酸酚妥拉明），QLS-101，BTQ-1902，VVN539，AGN-193408等。。

Discover which therapies are expected to grab the major open-angle glaucoma market share @ Open-Angle Glaucoma Market Report

发现哪些疗法有望占据主要的开角型青光眼市场份额@开角型青光眼市场报告

Open-Angle Glaucoma Overview

开角型青光眼概述

Open-angle glaucoma is a prevalent and serious ocular condition that impacts the optic nerve, potentially leading to vision impairment or blindness if left unattended. It stands as the most widespread type of glaucoma and typically advances slowly over time, frequently without any discernible symptoms during its initial stages.

开角型青光眼是一种普遍且严重的眼部疾病，会影响视神经，如果无人看管，可能导致视力障碍或失明。它是最普遍的青光眼类型，通常随着时间的推移缓慢进展，在其初始阶段经常没有任何可辨别的症状。

This is why it's often referred to as the 'silent thief of vision.' Primary open-angle glaucoma (POAG) represents the most common subtype, progressing gradually with elevated intraocular pressure. Normal-tension glaucoma (NTG) results in optic nerve damage even with normal intraocular pressure, while juvenile open-angle glaucoma is a rare early-onset variant that emerges in childhood or early adulthood.

这就是为什么它通常被称为“无声的视觉盗贼”原发性开角型青光眼（POAG）代表最常见的亚型，随着眼压升高而逐渐发展。正常眼压性青光眼（NTG）即使在眼压正常的情况下也会导致视神经损伤，而青少年开角型青光眼是一种罕见的早发性变异，出现在儿童期或成年早期。

In the early phases of open-angle glaucoma, noticeable symptoms or discomfort are typically absent. Peripheral vision loss usually emerges as the initial sign, occasionally going unnoticed as central vision remains unaffected. As the condition advances, tunnel vision can develop, and in severe instances, central vision loss may occur..

在开角型青光眼的早期阶段，通常不存在明显的症状或不适。周围视力丧失通常作为最初的体征出现，由于中央视力不受影响，偶尔会被注意到。随着病情的发展，隧道视力可能会发展，在严重的情况下，可能会发生中央视力丧失。。

Open-Angle Glaucoma Epidemiology Segmentation

开角型青光眼流行病学分割

The open-angle glaucoma epidemiology section provides insights into the historical and current open-angle glaucoma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. .

开角型青光眼流行病学部门提供有关历史和当前开角型青光眼患者库的见解以及个别七大国家的预测趋势。它通过探索众多研究和主要意见领袖的观点，有助于认识当前和预测趋势的原因。 .

The open-angle glaucoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

开角型青光眼市场报告提供了2019-2032年研究期间的流行病学分析，分为7MM分为：

Total Prevalent Cases of Glaucoma

青光眼流行病例总数

Total Diagnosed Prevalent Cases of Glaucoma

诊断为青光眼的流行病例总数

Type-specific Diagnosed Prevalent Cases of Glaucoma

特定类型诊断的青光眼流行病例

Type-specific Diagnosed Prevalent Cases of Open-Angle Glaucoma

开角型青光眼的特定类型诊断流行病例

Gender-specific Diagnosed Prevalent Cases of Open-Angle Glaucoma

性别特异性诊断开角型青光眼流行病例

Age-specific Diagnosed Prevalent Cases of Open-Angle Glaucoma

特定年龄诊断为开角型青光眼的流行病例

Open-Angle Glaucoma Treatment Market

开角型青光眼治疗市场

The primary goal of open-angle glaucoma treatment is to lower intraocular pressure to prevent further damage to the optic nerve. This is typically achieved through a combination of medical, laser, or surgical interventions. Medical treatment often involves the use of eye drops that either reduce the production of aqueous humor or increase its drainage.

开角型青光眼治疗的主要目标是降低眼压以防止进一步损伤视神经。这通常通过医疗，激光或手术干预的组合来实现。医疗通常涉及使用减少房水产生或增加其引流的滴眼液。

These medications help lower intraocular pressure and are usually the first line of defense against glaucoma..

这些药物有助于降低眼压，通常是预防青光眼的第一道防线。。

Laser therapy, such as selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT), can be employed to enhance the drainage of aqueous humor from the eye. These procedures are typically reserved for cases where eye drops alone are insufficient. In more advanced or refractory cases, surgical options like trabeculectomy or minimally invasive glaucoma surgery (MIGS) may be considered.

激光治疗，例如选择性激光小梁成形术（SLT）或氩激光小梁成形术（ALT），可用于增强眼房水的引流。这些程序通常保留用于单独滴眼液不足的情况。在更晚期或难治的病例中，可考虑手术选择，如小梁切除术或微创青光眼手术（MIGS）。

These surgeries create a new drainage pathway for the aqueous humor to reduce intraocular pressure..

这些手术为房水创造了一条新的引流通路，以降低眼压。。

Effective open-angle glaucoma management often involves a combination of these approaches tailored to the individual patient's needs, with regular monitoring to ensure that the disease is well-controlled and that vision loss is prevented or minimized. Early detection and ongoing treatment are essential in preserving the patient's vision and quality of life..

有效的开角型青光眼管理通常涉及针对个体患者需求量身定制的这些方法的组合，定期监测以确保疾病得到良好控制并且防止或最小化视力丧失。早期发现和持续治疗对于保持患者的视力和生活质量至关重要。。

To know more about open-angle glaucoma treatment, visit @ Open-Angle Glaucoma Treatment Drugs

要了解更多关于开角型青光眼治疗的信息，请访问@开角型青光眼治疗药物

Key Open-Angle Glaucoma Therapies and Companies

关键的开角型青光眼疗法和公司

NCX-470: Nicox Ophthalmics

NCX-470:Nicox Ophthalmics

PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)/Visiox Pharma

PDP-716（酒石酸溴莫尼定眼用混悬液）：Sun Pharma Advanced Research Company Limited（SPARC）/Visiox Pharma

TC-002 (latanoprost): TearClear

TC-002（拉坦前列素）：泪清

iDose TR (Travoprost Intraocular Implant): Glaukos Corporation

iDose TR（Travoprost眼内植入物）：Glaukos Corporation

Sepetaprost/DE-126/ONO-9054/STN-1012600: Santen Inc/Ono Pharmaceutical

Sepetaprost/DE-126/ONO-9054/STN-1012600:Santen Inc/ONO Pharmaceutical

Catioprost/DE-130A/STN1013001: Santen Pharmaceuticals

Catioprost/DE-130A/STN1013001:Santen Pharmaceuticals

Citicoline eye drops 2%: Omikron Italia S.r.l./OPIS Spain

Citicoline滴眼液2%：Omikron Italia S.r.l./OPIS Spain

H-1337: D. Western Therapeutics Institute (DWTI)

H-1337:D。Western Therapeutics Institute（DWTI）

OTX-TIC: Ocular Therapeutix, Inc.

OTX-TIC:眼科治疗，股份有限公司。

LL-BMT1: MediPrint Ophthalmics (formerly Leo Lens Pharma)

LL-BMT1:MediPrint Ophthalmics（前身为Leo Lens Pharma）

TRS01: Tarsier Pharma

TRS01:Tarsier Pharma

POLAT-001 (Liposomal latanoprost): Peregrine Ophthalmic

POLAT-001（脂质体拉坦前列素）：Peregrine Ophthalmic

Nyxol (Phentolamine Mesylate): Ocuphire Pharma

Nyxol（酚妥拉明甲磺酸盐）：Ocuphire Pharma

QLS-101: Qlaris Bio, Inc.

QLS-101:Qlaris Bio，股份有限公司。

BTQ-1902: Betaliq, Inc.

BTQ-1902:Betaliq，股份有限公司。

VVN539: VivaVision Biotech, Inc.

VVN539: VivaVision Biotech, Inc.

AGN-193408: Abbvie

AGN-193408：Abbvie

Learn more about the FDA-approved drugs for open-angle glaucoma @ Drugs for Open-Angle Glaucoma Treatment

了解更多关于FDA批准的开角型青光眼药物@开角型青光眼治疗药物

Open-Angle Glaucoma Market Dynamics

开角型青光眼市场动态

The dynamics of the open-angle glaucoma market are expected to change in the coming years. The surge in open-angle glaucoma cases prompts the need for enhanced treatment options. Increasing recognition of early detection's role in minimizing disease impact fuels higher screening and diagnosis rates.

预计未来几年开角型青光眼市场的动态将会发生变化。开角型青光眼病例的激增促使需要加强治疗选择。越来越多地认识到早期发现在减少疾病影响方面的作用，可以提高筛查和诊断率。

As awareness spreads and healthcare infrastructure improves, emerging markets hold promising opportunities for growth in the open-angle glaucoma market..

随着意识传播和医疗基础设施的改善，新兴市场为开角型青光眼市场的增长提供了有希望的机会。。

Furthermore, the open-angle glaucoma pipeline is very robust; many potential therapies are being investigated for the treatment of open-angle glaucoma, and it is safe to predict that the treatment space will significantly impact the open-angle glaucoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the open-angle glaucoma market in the 7MM..

此外，开角型青光眼管道非常坚固；目前正在研究许多用于治疗开角型青光眼的潜在疗法，并且可以安全地预测在预测期间治疗空间将显着影响开角型青光眼市场。此外，预期引入具有改善的功效和诊断率的进一步改善的新兴疗法将推动7MM中开角型青光眼市场的增长。。

However, several factors are impeding the growth of the open-angle glaucoma market. Inadequate patient adherence to lifelong medication and infrequent follow-up care can result in less-than-ideal treatment outcomes. Stringent regulatory protocols and approval procedures may impede the timely introduction of new treatments and innovations.

然而，有几个因素阻碍了开角型青光眼市场的增长。患者对终身药物依从性不足以及不常见的随访护理可能导致治疗效果不理想。严格的监管协议和审批程序可能会妨碍及时引入新的治疗和创新。

Moreover, open-angle glaucoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the open-angle glaucoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists.

此外，开角型青光眼治疗带来了重大的经济负担，并扰乱了患者的整体健康和生活质量。此外，开角型青光眼市场的增长可能会被新兴疗法的失败和中止，负担不起的定价，市场准入和报销问题以及医疗保健专家短缺所抵消。

In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the open-angle glaucoma market growth..

此外，未确诊，未报告的病例和对该疾病的不了解也可能影响开角型青光眼市场的增长。。

Report Metrics

报告指标

Details

细节

Study Period

学习期

2019–2032

2019–2032

Coverage

新闻报道

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

7MM[美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本]

Key Open-Angle Glaucoma Companies

关键开角型青光眼公司

Nicox Ophthalmics, Sun Pharma Advanced Research Company Limited (SPARC), Visiox Pharma, TearClear, Glaukos Corporation, Ono Pharmaceutical, Santen Pharmaceuticals, Omikron Italia S.r.l., OPIS Spain, D. Western Therapeutics Institute (DWTI), Ocular Therapeutix, Inc., MediPrint Ophthalmics (formerly Leo Lens Pharma), Tarsier Pharma, Peregrine Ophthalmic, Ocuphire Pharma, Qlaris Bio, Inc., Betaliq, Inc., VivaVision Biotech, Inc., Abbvie, and others .

Nicox Ophthalmics，Sun Pharma Advanced Research Company Limited（SPARC），Visiox Pharma，TearClear，Glaukos Corporation，Ono Pharmaceutical，Santen Pharmaceuticals，Omikron Italia S.r.l.，OPIS Spain，D.Western Therapeutics Institute（DWTI），Ocular Therapeutix，Inc.，MediPrint Ophthalmics（以前称为Leo Lens Pharma），Tarsier Pharma，Peregrine Ophthalmic，Ocuphire Pharma，Qlaris Bio，Inc，Inc.，VivaVision Biotech，Inc.，Abbvie等。

Key Open-Angle Glaucoma Therapies

关键的开角型青光眼治疗

NCX-470, PDP-716 (Brimonidine Tartrate Ophthalmic Suspension), TC-002 (latanoprost), iDose TR (Travoprost Intraocular Implant), Sepetaprost/DE-126/ONO-9054/STN-1012600, Catioprost/DE-130A/STN1013001, Citicoline eye drops 2%, H-1337, OTX-TIC, LL-BMT1, TRS01, POLAT-001 (Liposomal latanoprost), Nyxol (Phentolamine Mesylate), QLS-101, BTQ-1902, VVN539, AGN-193408, and others .

NCX-470，PDP-716（酒石酸溴莫尼定酒石酸溴莫尼定眼用悬浮液），TC-002（拉坦前列素），iDose TR（Travoprost眼内植入物），Sepetaprost/DE-126/ONO-9054/STN-1012600，Catioprost/DE-130A/STN1013001，胞磷胆碱滴眼液2%，H-1337，OTX-TIC，LL-BMT1，TRS01，POLAT-001（脂质体拉坦前列前列素），Nyxol（苯甲苯甲胺甲磺酸盐），QLS-101，BTQ-1902，VVVVN539，AGN-193408，等等，等等。

Scope of the Open-Angle Glaucoma Market Report

开角型青光眼市场报告的范围

Therapeutic Assessment: Open-Angle Glaucoma current marketed and emerging therapies

治疗评估：开角型青光眼目前市场和新兴疗法

Open-Angle Glaucoma Market Dynamics: Conjoint Analysis of Emerging Open-Angle Glaucoma Drugs

开角型青光眼市场动态：新兴开角型青光眼药物的联合分析

Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

竞争智力分析：SWOT分析和市场准入策略

Unmet Needs, KOL's views, Analyst's views, Open-Angle Glaucoma Market Access and Reimbursement

未满足的需求，KOL的观点，分析师的观点，开角型青光眼的市场准入和报销

Discover more about open-angle glaucoma drugs in development @ Open-Angle Glaucoma Clinical Trials

在开发中发现更多关于开角型青光眼药物的信息@开角型青光眼临床试验

Table of Contents

目录

1.

1.

Open-Angle Glaucoma Market Key Insights

开角型青光眼市场关键见解

2.

2.

Open-Angle Glaucoma Market Report Introduction

开角型青光眼市场报告简介

3.

3.

Open-Angle Glaucoma Market Overview at a Glance

开角型青光眼市场概况一目了然

4.

4.

Open-Angle Glaucoma Market Executive Summary

开角型青光眼市场执行摘要

5.

5.

Disease Background and Overview

疾病背景和概述

6.

6.

Open-Angle Glaucoma Treatment and Management

开角型青光眼的治疗和管理

7.

7.

Open-Angle Glaucoma Epidemiology and Patient Population

开角型青光眼流行病学和患者人群

8.

8.

Patient Journey

耐心之旅

9.

9.

Open-Angle Glaucoma Marketed Drugs

开角型青光眼销售的药物

10.

10.

Open-Angle Glaucoma Emerging Drugs

开角型青光眼新兴药物

11.

11.

Seven Major Open-Angle Glaucoma Market Analysis

七大开角型青光眼市场分析

12.

12.

Open-Angle Glaucoma Market Outlook

开角型青光眼市场前景

13.

13.

Potential of Current and Emerging Therapies

当前和新兴疗法的潜力

14.

14.

KOL Views

KOL Views

15.

15.

Unmet Needs

未满足的需求

16.

16.

SWOT Analysis

SWOT分析

17.

17.

Appendix

附录

18.

18.

DelveInsight Capabilities

DelveInsight功能

19.

19.

Disclaimer

免责声明

20.

20.

About DelveInsight

关于DelveInsight

Related Reports

相关报告

Open-Angle Glaucoma Pipeline

开角型青光眼管道

Open-Angle Glaucoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key open-angle glaucoma companies, including Qlaris Bio, Ocular Therapeutix, SALVAT, Aerpio Pharmaceuticals, Ocularis Pharma, PolyActiva, AbbVie, Annexon, Skye Bioscience, GrayBug, Quark Pharmaceuticals, among others..

开角型青光眼管道洞察力-2023报告提供了有关管道景观，管道药物概况（包括临床和非临床阶段产品）以及关键开角型青光眼公司（包括Qlaris Bio，Ocular Therapeutix，SALVAT，Aerpio Pharmaceuticals，Ocularis Pharma，PolyActiva，AbbVie，Annexon，Skye Bioscience，GrayBug，夸克制药等。。

Open-Angle Glaucoma Epidemiology

开角型青光眼流行病学

Open-Angle Glaucoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted open-angle glaucoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

开角型青光眼流行病学预测-2032报告深入了解了7MM，即美国，EU5（德国，西班牙，意大利，法国和英国）和日本的疾病，历史和预测的开角型青光眼流行病学。

Glaucoma Market

青光眼市场

Glaucoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key glaucoma companies, including Novaliq GmbH, Kowa, D. Western Therapeutics Institute, Sun Pharma Advanced Research Company, among others..

青光眼市场见解，流行病学和市场预测-2032年报告深入了解该疾病，历史和预测的流行病学，以及市场趋势，市场驱动因素，市场障碍和主要青光眼公司，包括Novaliq GmbH，Kowa，D。Western Therapeutics Institute，Sun Pharma Advanced Research Company等。。

Glaucoma Pipeline

青光眼管道

Glaucoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key glaucoma companies, including Qlaris Bio, Inc., Nicox, Allysta Pharmaceutical, ONL Therapeutics, JeniVision, Inc., Ocular Therapeutix, Laboratoires Thea, Optifye Therapeutics, PolyActiva, Laboratorios Sophia S.A de C.V., pH Pharma, Santen Pharmaceutical, Peregrine Ophthalmic, Envisia Therapeutics, Tarsier Pharma, Ocular Therapeutix, Aerpio Therapeutics, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, MediPrint Ophthalmics, Inc., Noveome Biotherapeutics, Novaliq GmbH, Western Therapeutics, Sun Pharma Advanced Research Company, GrayBug inc., Biozeus, Ocuphire Pharma, VISUS THERAPEUTICS, Eyevensys, Skye Bioscience inc, Eyebiotech limited, Stuart Therapeutics, Q BioMed Inc., TALLC Inc., Mitotech, Cloudbreak Pharmaceutical, Cellix Bio, Galimedix Therapeutics, Isarna Therapeutics, Ripple Therapeutics, InMed Pharmaceuticals, Arctic Vision,  HK inno.N, Avirmax Inc., among others..

青光眼管道洞察力-2023报告提供了有关管道景观，管道药物概况（包括临床和非临床阶段产品）以及关键青光眼公司的全面见解，包括Qlaris Bio，Inc.，Nicox，Allysta Pharmaceutical，ONL Therapeutics，JeniVision，Inc.，Ocular Therapeutix，Laboratoires Thea，Optifye Therapeutics，PolyActiva，Laboratorios Sophia S.A de C.V.，pH Pharma，Santen Pharmaceutical，Peregrine Ophthalmic，Envisia Therapeutics，Tarsier Pharma，Ocular Therapeutix，Aerpio Therapeutics，Whitecap Biosciences，LLC，Chong Kun Dang Pharmaceutical，MediPrint Ophthalmics，Inc.，Noveome Biotherapeutics，Novaliq GmbH，Western Therapeutics，Sun Pharma Advanced Research Company，GrayBug Inc.，Bi，VISUS THERAPEUTICS，Eyevensys，Skye Bioscience inc，Eyebiotech limited，Stuart THERAPEUTICS，Q BioMed inc.，TALLC inc.，Mitotech，Cloudbreak Pharmaceutical，Cellix Bio，Galimedix THERAPEUTICS，Isarna THERAPEUTICS，Ripple THERAPEUTICS，InMed Pharmaceuticals，Arctic Vision，HK inno。N、 Avirmax Inc.等。。

About DelveInsight

关于DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve..

DelveInsight是专注于生命科学的领先商业顾问和市场研究公司。它通过提供全面的端到端解决方案来支持制药公司，以提高其绩效。通过我们基于订阅的平台PharmDelve，可以轻松访问所有医疗保健和制药市场研究报告。。

Contact UsShruti Thakur [email protected]   +1(919)321-6187 www.delveinsight.com

Contact UsShruti Thakur [email protected]   +1(919)321-6187 www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

徽标：https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP

来源DelveInsight商业研究，LLP